Immunoglobulin G to human herpesvirus 6 (HHV-6) and cytomegalovirus (CMV) in sera from solid organ recipients was measured by an enzyme-linked immunoassay (ELISA) before and after transplant. The HHV-6 ELISA was developed from glycine extracts of HHV-6-infected and uninfected HSB-2 cells. At a serum dilution of 1:500, 80 (91%) of 88 recipients were seropositive for HHV-6 before transplant, while only 14 (16%) were seropositive for CMV. Posttransplant HHV-6 serologic rises were observed in 38 (43%) recipients; rises in 25 of these recipients were associated with primary CMV infection. Titration of sera revealed much higher HHV-6 titer rises among those with primary CMV infection than among those with CMV reactivation or with no CMV infection. Elevated HHV-6 antibody titers persisted for up to 2 years after primary CMV infection. No correlation was noted between CMV and HHV-6 antibody titers in individual serum samples.
Human herpesvirus 6 (HHV-6) was first described in 1986 as a virus infecting B lymphocytes of six patients with lymphoproliferative disorders (22) . The virus is now known to infect T cells in vitro (19) , and primary human infection may cause the syndrome of roseola infantum (3, 25) . The reported HHV-6 seroprevalence has ranged from an early report of 2% (4 of 220) (22) to as high as 98% (41 of 42) (15) , with recent studies tending to confirm a high seroprevalence in ail populations surveyed (4, 5, 15, 16, 18, 21, 23) . Most serologic surveys have been done by indirect immunofluorescence with infected cultured cells. Interpretation of these assays is complicated by variations in techniques and reagents and an element of subjectivity in reading results. Enzyme-linked immunosorbent assays (ELISAs) and immunoblot (Western blot) assays for have been reported (1, 23) , but published experience so far is limited. A few reported cases of HHV-6 seroconversion or serologic rise have been found to occur in conjunction with cytomegalovirus (CMV) seroconversion and to be accompanied by CMV-like syndromes, thus raising questions about crossreactivity (12, 14, 17, 20) . In addition to this concern is the observation of a limited DNA homology between CMV and HHV-6 (10) .
During a past investigation of the serology and virology of CMV infection in organ transplant recipients, we collected serum specimens which were subsequently characterized in terms of the CMV antibody and the CMV infection status of the respective recipients. Using some of these sera and antigens extracted from HHV-6-infected cells, we developed and tested a new HHV-6 ELISA to determine (i) the proportion of recipients with HHV-6 antibody pretransplant, (ii) changes in HHV-6 antibody levels posttransplant in those with various categories of CMV infection, and (iii) whether there is a correlation between HHV-6 and CMV antibody titers which might suggest cross-reactivity. The An SA of >0.1 was considered positive; in titrations, the highest dilution giving this SA was read as the endpoint.
RESULTS
Single-dilution ELISA. Sera tested at a single 1:500 dilution gave a wide range of signals, with SA readings ranging from 0.0, presumably representing HHV-6-seronegative sera, to 1.5 (Fig. 1) the proportion of those recipients with posttransplant serologic rises to HHV-6 antibody. An antibody rise was considered to have occurred with a twofold increase in the SA, or an absolute increase of 0.4 units. By these criteria, over 40% of recipients had an antibody rise to HHV-6 in the period from 6 to 40 weeks posttransplant (Table 1 ). HHV-6 antibody rises were strongly associated with CMV seroconversion; 75% of those undergoing CMV seroconversion (negative to positive) had a concomitant HHV-6 antibody rise (usually from a positive to a higher positive). This was more than twice the incidence of HHV-6 antibody rises seen in groups with no CMV infection (who remained CMV seronegative) or who were CMV seropositive. In the latter category, 12 of 14 were known to have active CMV infection (viral shedding) posttransplant.
HHV-6 ELISA titers. In order to provide more precise information about the magnitude of the HHV-6 serologic rises, titers of pre-and posttransplant sera from 15 patients in each of the groups (no CMV infection, primary CMV, or CMV reactivation and reinfection with documented viral shedding) were determined to obtain an endpoint dilution. Results are shown in Fig. 2 . Pretransplant titers were similar in all groups. However, in the posttransplant period, almost all of those with primary CMV infection showed a rise in HHV-6 antibody to >1:8,000, whereas only one of those in the other two groups (including all of those identified as having titer rises [ Table 1 ]) had a posttransplant HHV-6 antibody titer of >1:8,000. HHV-6 titers in some of those with primary CMV infection reached 1:512,000.
We also had an opportunity to examine serum specimens from three renal transplant candidates before and after they acquired primary CMV infection from pretransplant blood transfusions. These patients were not on immunosuppressive regimens. HHV-6 antibody titers for these three patients at 3 to 4 months posttransfusion (with documented CMV seroconversion and shedding) were 1:8,000, 1:64,000, Time course of HHV-6 antibody rise. The duration of the HHV-6 antibody rise associated with primary CMV infection was examined in three recipients for which long-term follow-up sera were available. HHV-6 antibody titers were 1:64,000 at 1,018 days, 1:512,000 at 685 days, and 1:32,000 at 856 days. These titers were unchanged, increased by one dilution, and decreased by four dilutions, respectively, when compared with values obtained from the same recipients within several months of transplant. Figure 3 shows the evolution of HHV-6 titers in two of these individuals over time. Titers rose rapidly to high levels by the time of onset of CMV shedding and were relatively sustained over the follow-up period.
Comparison of CMV and HHV-6 titers. Antibody titers to HHV-6 and CMV in 18 serum specimens with high singledilution absorbances or measured titers of either antibody were compared (Fig. 4) . The highest CMV titers tended to be seen in those with secondary CMV infection (reactivation and reinfection), whereas the highest HHV-6 antibody titers tended to be seen in those with primary CMV infection. In individual serum specimens, CMV and HHV-6 titers differed greatly.
DISCUSSION
Using an HHV-6 ELISA developed from glycine-extracted infected and uninfected cell antigens, we found a high seroprevalence of HHV-6 infection and observed that HHV-6 antibody rises associated with primary CMV infection occurred after transfusion or transplantation. Very high anti-HHV-6 titers were reached. These very high titers were not seen in sera from those uninfected with CMV or those undergoing CMV reactivation or reinfection and having high titers of CMV antibody.
The high base-line seroprevalence of HHV-6 infection is consistent with recent serologic surveys done by immunofluorescence assays or ELISA (15, 21, 23) , although there appears to be no consensus regarding a precise criterion for seropositivity, and most normal adult populations appear to have a relatively low titer of HHV-6 antibody (21), similar to our pretransplant samples (Fig. 1) . Variable sensitivity and interpretation of immunofluorescence assays is probably responsible for the wide divergence in seroprevalence reported to date. Whether the absence of HHV-6 antibody detectable by a particular assay implies susceptibility to primary infection can only be established by further serologic and virologic studies. Of eight recipients classified in this study as HHV-6 seronegative at the time of transplant, six became seropositive posttransplant (two with primary CMV infection).
During primary CMV infection, HHV-6 antibody levels rise rapidly and usually to very high levels. We generally observed HHV-6 antibody rises rather than seroconversions. Possible explanations for this phenomenon might include (i) cross-reactivity between CMV and HHV-6, (ii) increased reactivity to non-CMV antigens because of polyclonal B-cell activation during primary CMV infection analogous to that seen in Epstein-Barr virus mononucleosis, and (iii) a true increase in HHV-6 viral activity (reactivation) as a result of CMV effects on leukocytes (stimulation, suppression) or of viral interactions like those that have been postulated to occur between herpesviruses and human immunodeficiency virus (11) .
In the absence of data from viral isolation studies (which are in progress), assessment of the relative likelihood of these possibilities must be somewhat tentative. Because (24) suggests that, as with other herpesviruses, HHV-6 infection may complicate the posttransplant period.
